title: Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer.
abstract: OBJECTIVE
  Docetaxel-based chemotherapy against castration-resistant prostate cancer (CRPC) has recently been shown to be effective and tolerable. The objective of this study was to retrospectively evaluate the efficacy and toxicity of low-dose docetaxel in combination with dexamethasone.
  
  
  METHODS
  Thirty-seven CRPC patients were administered a treatment regimen consisting of 50 mg/m2 docetaxel once every 3-4 weeks and 1 mg dexamethasone daily at our institution, between November 2004 and April 2014.
  
  
  RESULTS
  Twenty-four patients (65%) had a decrease in serum prostate-specific antigen (PSA) >50%. The median overall survival (OS) and PSA progression-free survival were 26.2 and 10.0 months, respectively. Ten of 12 patients (83%) taking analgesic agents reduced their intake because of decreased pain levels. Grade 3 febrile neutropenia occurred in 2 patients (5%). Nonhematological toxicities were less frequent but sometimes severe. Treatment-related death occurred in 2 octogenarian patients, 1 due to gastric bleeding and the other due to infective endocarditis.
  
  
  CONCLUSIONS
  Low-dose docetaxel in combination with dexamethasone is feasible in Japanese CRPC patients. Hematological toxicity is less than that seen with standard docetaxel therapy, but it is necessary to monitor patients for severe nonhematological toxicities, particularly very elderly patients.
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Miura
authors.forename: Nozomu
authors.initials: N
authors.lastname: Tanji
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yanagihara
authors.forename: Terutaka
authors.initials: T
authors.lastname: Noda
authors.forename: Seiji
authors.initials: S
authors.lastname: Asai
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nishimura
authors.forename: Akitomi
authors.initials: A
authors.lastname: Shirato
authors.forename: Yuki
authors.initials: Y
authors.lastname: Miyauchi
authors.forename: Tadahiko
authors.initials: T
authors.lastname: Kikugawa
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Yokoyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D003907:Dexamethasone